Literature DB >> 27197176

Autocrine Secretion of Progastrin Promotes the Survival and Self-Renewal of Colon Cancer Stem-like Cells.

Julie Giraud1, Laura M Failla2, Jean-Marc Pascussi1, Ebba L Lagerqvist1, Jérémy Ollier1, Pascal Finetti3, François Bertucci3, Chu Ya1, Imène Gasmi1, Jean-François Bourgaux4, Michel Prudhomme4, Thibault Mazard5, Imade Ait-Arsa5, Leila Houhou6, Daniel Birnbaum3, André Pélegrin5, Charles Vincent5, James G Ryall7, Dominique Joubert1, Julie Pannequin8, Frédéric Hollande9.   

Abstract

Subpopulations of cancer stem-like cells (CSC) are thought to drive tumor progression and posttreatment recurrence in multiple solid tumors. However, the mechanisms that maintain stable proportions of self-renewing CSC within heterogeneous tumors under homeostatic conditions remain poorly understood. Progastrin is a secreted peptide that exhibits tumor-forming potential in colorectal cancer, where it regulates pathways known to modulate colon CSC behaviors. In this study, we investigated the role of progastrin in regulating CSC phenotype in advanced colorectal cancer. Progastrin expression and secretion were highly enriched in colon CSC isolated from human colorectal cancer cell lines and colon tumor biopsies. Progastrin expression promoted CSC self-renewal and survival, whereas its depletion by RNA interference-mediated or antibody-mediated strategies altered the homeostatic proportions of CSC cells within heterogeneous colorectal cancer tumors. Progastrin downregulation also decreased the frequency of ALDH(high) cells, impairing their tumor-initiating potential, and inhibited the high glycolytic activity of ALDH(high) CSC to limit their self-renewal capability. Taken together, our results show how colorectal CSC maintain their tumor-initiating and self-renewal capabilities by secreting progastrin, thereby contributing to the tumor microenvironment to support malignancy. Cancer Res; 76(12); 3618-28. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27197176     DOI: 10.1158/0008-5472.CAN-15-1497

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

Review 1.  Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells.

Authors:  Ugo Testa; Elvira Pelosi; Germana Castelli
Journal:  Med Sci (Basel)       Date:  2018-04-13

2.  Pan-Cancer Single-Cell Analysis Reveals the Core Factors and Pathway in Specific Cancer Stem Cells of Upper Gastrointestinal Cancer.

Authors:  Leijie Li; Yujia Zhang; Yongyong Ren; Zhiwei Cheng; Yuening Zhang; Xinbo Wang; Hongyu Zhao; Hui Lu
Journal:  Front Bioeng Biotechnol       Date:  2022-05-13

3.  Oncogenic Signalling of PEAK2 Pseudokinase in Colon Cancer.

Authors:  Céline Lecointre; Elise Fourgous; Ingrid Montarras; Clément Kerneur; Valérie Simon; Yvan Boublik; Débora Bonenfant; Bruno Robert; Pierre Martineau; Serge Roche
Journal:  Cancers (Basel)       Date:  2022-06-16       Impact factor: 6.575

4.  Progastrin: a potential predictive marker of liver metastasis in colorectal cancer.

Authors:  David A Westwood; Oneel Patel; Christopher Christophi; Arthur Shulkes; Graham S Baldwin
Journal:  Int J Colorectal Dis       Date:  2017-04-21       Impact factor: 2.571

5.  The m6A reading protein YTHDF3 potentiates tumorigenicity of cancer stem-like cells in ocular melanoma through facilitating CTNNB1 translation.

Authors:  Yangfan Xu; Xiaoyu He; Shanzheng Wang; Baofa Sun; Ruobing Jia; Peiwei Chai; Fang Li; Ying Yang; Shengfang Ge; Renbing Jia; Yun-Gui Yang; Xianqun Fan
Journal:  Oncogene       Date:  2022-02-03       Impact factor: 9.867

6.  Acute effects of N-terminal progastrin fragments on gastric acid secretion in man.

Authors:  Jens P Goetze; Carsten P Hansen; Jens F Rehfeld
Journal:  Physiol Rep       Date:  2017-03

7.  The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients.

Authors:  Benoit You; Frédéric Mercier; Eric Assenat; Carole Langlois-Jacques; Olivier Glehen; Julien Soulé; Léa Payen; Vahan Kepenekian; Marie Dupuy; Fanny Belouin; Eric Morency; Véronique Saywell; Maud Flacelière; Philippe Elies; Pierre Liaud; Thibault Mazard; Delphine Maucort-Boulch; Winston Tan; Bérengère Vire; Laurent Villeneuve; Marc Ychou; Manish Kohli; Dominique Joubert; Alexandre Prieur
Journal:  EBioMedicine       Date:  2019-12-24       Impact factor: 8.143

8.  SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemness.

Authors:  Leiming Xia; Fan Yang; Xiao Wu; Suzhi Li; Chen Kan; Hong Zheng; Siying Wang
Journal:  Cancer Cell Int       Date:  2021-07-03       Impact factor: 5.722

9.  Transcriptional inhibition by CDK7/9 inhibitor SNS-032 abrogates oncogene addiction and reduces liver metastasis in uveal melanoma.

Authors:  Jing Zhang; Shenglan Liu; Qianyun Ye; Jingxuan Pan
Journal:  Mol Cancer       Date:  2019-09-16       Impact factor: 27.401

10.  Cancer Stem Cells of Diffuse Large B Cell Lymphoma Are Not Enriched in the CD45+CD19- cells but in the ALDHhigh Cells.

Authors:  Shupeng Song; Yongguo Li; Kaili Zhang; Xi Zhang; Yanxin Huang; Mingyan Xu; Shuangxing Li; Xue Guan; Tao Yang; Zhiyu Liu; Jie Jiang; Yunping Luo; Yinghua Lan
Journal:  J Cancer       Date:  2020-01-01       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.